

ISOLATION AND STRUCTURE OF
SF-1902 A₅, A NEW GLOBOMYCIN
ANALOGUE

SHOJI OMOTO, HIROKO SUZUKI and
SHIGEHARU INOUE

Research Laboratories, Meiji Seika Kaisha, Ltd.
Morooka-cho Kohoku-ku, Yokohama 222, Japan

(Received for publication September 12, 1978)

SF-1902 is a solvent-soluble, neutral antibiotic produced by *Streptomyces hygroscopicus* SF-1902¹⁾. It shows antibacterial activity only against Gram-negative bacteria²⁾. HPLC analysis of the sample seemingly homogeneous on TLC (silica gel, chloroform-methanol, 5:1, or acetone-benzene, 2:1) disclosed the presence of several minor components and one major component SF-1902, as shown in Fig. 1. Those were separated from each other by using a semi-preparative LC column of μ Bondapak C₁₈. Among these, SF-1902 and SF-1902 A₅ were obtained as crystals. When 850 mg of the crude sample of SF-1902 was purified by recrystallization and semi-preparative LC, 530 mg of SF-1902, 32 mg of A₂, 100 mg of A₃, 50 mg of A₄ and 75 mg of A₅ were obtained. SF-1902, a major component, was identified with globomycin³⁾ by the direct comparison including ORD curves in chloroform. Among these minor components, only A₅ was obtained as homogeneous

crystals. Further purification and the structural studies of other minor components are now under study.

Fig. 1. HPLC analysis of SF-1902 preparation
Column: μ Bondapak C₁₈ (8 mm \times 300 mm)
Solvent: Acetonitrile-water, 60:40
Flow rate: 1.7 ml/min.




Fig. 2. IR spectrum of SF-1902 A₅ (KBr)





Fig. 3. 100 MHz PMR spectrum of SF-1902 A₅ in CDCl₃

Physico-chemical Properties of SF-1902 A₅ (I)

SF-1902 A₅ (I) was separated only by HPLC, but not by TLC so far. It shows solubility very similar to SF-1902. I was obtained as fine needles from 60% aqueous acetonitrile and possessed the following physico-chemical characteristics: m.p. 113~117°C, $[\alpha]_D^{20} -16^\circ$ (*c* 0.7, CHCl₃) (after drying at 70°C *in vacuo* for 10 hours), PMR (Fig. 2, CDCl₃), 3.2 ppm (NMe), MS M⁺ 683 (C₃₄H₆₁N₅O₉), Anal. Calcd. for C₃₄H₆₁N₅O₉: C, 59.71; H, 8.99; N, 10.24% Found: C, 59.85; H, 8.85; N, 10.30%; IR (Fig. 3, KBr), 2960, 2930, 1740, 1650 and 1540 cm⁻¹, very similar to that of SF-1902.

Components of I

Acid hydrolysis followed by the Dowex 50WX2 chromatography (0.1 M pyridine-acetate buffer, pH 3.1) gave each one mole of *L*-allo-threonine, *L*-serine, glycine, *N*-methylleucine and *L*-allo-isoleucine. These amino acid components were identical with those of globomycin. Each of them was identified by PPC, amino acid analysis, PMR and optical rotation. *allo*-Threonine structure was confirmed by comparing its retention time on GLC as its methyl ester *N*-trifluoroacetate with those of threonine and *allo*-threonine. *allo*-Threonine was eluted in 3.2 minutes, while threonine was eluted in 2.2 minutes (0.75% OV-1 on Gas-Chrom Q 1.2 m, 85°C, He flow rate: 2.2 ml/min.). From these

data, SF-1902 A₅ (I) is considered to be a homologue of globomycin. CMR spectrum of I in CDCl₃ is indistinguishable from that of globomycin except for 28~32 ppm region indicating the presence of extra 2 methylene units. GC-MS analysis of the fatty acid moiety (II) of I, as its methyl ester acetate, gave a molecular ion at *m/e* 272, indicative of an original molecular formula of II as C₁₂H₂₄O₈ (retention time; 6.1 minutes, RT_{nonadecane}; 0.76). The structure of II was finally confirmed to be *threo*-3-hydroxy-2-methylundecanoic acid by GC and NMR comparisons^{4,5} of it and the synthetic reference sample of *threo* and *erythro* isomers prepared from nonanal and 2-bromopropionic acid by the REFORMATSKY reaction according to BELLAR-SOUED *et al.*⁶.

Structure of I

The amino acid sequence was determined by the application of mass spectrometry and found to be identical with that of globomycin. Alkali treatment of I gave an open chain compound (III), which was permethylated.





Fig. 4. The mass spectrum of the permethylated and the perdeuteromethylated (parentheses) derivatives of **III**




The mass spectrum of the permethylated derivative of **III** (Fig. 4) gave a molecular ion at m/e 813 accompanied by the peaks at m/e 711, 582, 467 and 340 derived from the cleavage at the peptide bonds. The peak at m/e 340 indicated that the acyl group attached to N-methylleucine was C_{12} -carboxylic acid instead of C_{10} -carboxylic acid in globomycin. Since the perdeuteromethylated analogue of **III** gave N-acyl-methylleucine fragment at m/e 343 accompanied by the peak at m/e 473 for N-methylleucyl-*allo*-isoleucine fragment, the sequence of N-acyl-N-methylleucyl-*allo*-isoleucine was clearly determined.

The carboxyl group of glycine should be bound to one of the hydroxyl groups to form a lactone ring, since **I** is neutral. The site of lactone ring formation was shown to be identical with that of globomycin because 50~80 ppm region of CMR was superimposable with that of globomycin. Assignment of these CMR signals has been carried out by the application of known chemical shift data of amino acids⁷⁾ and off resonance data. In the CMR of **I**, 7 signals are observed in the region of 50~80 ppm in $CDCl_3$. Of these, 6 signals from 56.6 to 68.5 ppm can be assigned to the following carbons: 56.6 ppm: *allo*-Ileu- α ; 58.5 ppm: Ser- α ; 59.2 ppm: *allo*-Thr- α ; 61.3 ppm: Ser- β ; 66.8 ppm: *allo*-Thr- β ; 68.5 ppm: Me-Leu- α . The downfield shifts of α -carbons of serine and *allo*-threonine with the upfield shifts of β -carbons of these amino acids on acetylation indicated that the hydroxyl groups of these amino acids were free in **I**. Furthermore, the signal at 76.7 ppm can be assigned to C-3 of 3-hydroxy-2-methylundecanoic acid in

which the hydroxyl group has been esterified with the carboxyl group of glycine to form a lactone ring. Since C-3 of **II** is observed at 73.4 ppm in $CDCl_3$, it is rational to assign the signal at 76.7 ppm in **I** to the signal of C-3 of **II**. The downfield shift by 3.3 ppm in **I** of this signal strongly suggests that the hydroxyl group of **II** is esterified with the carboxyl group of glycine to form a lactone ring. These results lead to the structure **II** for SF-1902 A₅.

SF-1902 A₅ shows antibacterial activity stronger than globomycin. Details of its bioactivity will be reported in a subsequent paper discussing the structure-activity relationship of SF-1902 complex.



Acknowledgement

The authors are very grateful for a gift of globomycin to Dr. M. ARAI, Sankyo Co. (Tokyo). They also wish to thank Ms. S. MIKI for mass spectra.

References

- 1) SHOMURA, T.; S. OMOTO, M. KOJIMA, H. WATANABE, K. TOTSUGAWA, S. INOUE & T. NIIDA: Studies on a new antibiotic SF-1902. I. Producing microorganism, isolation and characterization. Sci. Reports, Meiji Seika Kaisha 17: 7~11, 1976
- 2) MIYAUCHI, K.; T. WATANABE, T. YOSHIDA, T.

- WATANABE, Y. YUSA, C. MORIYAMA, S. OMOTO, T. SHOMURA, M. KOJIMA, S. INOUE & T. NIIDA: Studies on a new antibiotic SF-1902. II. Biological studies. *Sci. Reports, Meiji Seika Kaisha* 17: 12~15, 1978
- 3) NAKAJIMA, M.; M. INUKAI, T. HANEISHI, A. TERAHARA, M. ARAI, T. KINOSHITA & C. TAMURA: Globomycin, a new peptide antibiotic with spheroplast-forming activity. III. Structural determination of globomycin. *J. Antibiotics* 31: 426~432, 1978
- 4) BUSE, C. T. & C. H. HEATHCOCK: Acyclic stereoselection. 2. Synthesis of 3-hydroxy-2-methyl- and 3-hydroxy-2,4-dimethylcarboxylic acids. *J. Am. Chem. Soc.* 99: 8109~8110, 1977
- 5) CANCEILLE, J.; J.-J. BASSELIER & J. JACQUES: On the stereochemistry of the REFORMATSKY reaction. *Bull. Soc. Chim. Fr.* 1963: 1906~1908, 1963
- 6) BELLARSOUED, M.; R. COUFFIGNAL & M. GAUDEMAR: The direct synthesis of β -hydroxy acids *via* the REFORMATSKY reaction. *J. Organometal. Chem.* 61: 9, 1973
- 7) HORSLEY, W.; H. STERNLICHT & J. S. COHEN: Carbon-13 magnetic resonance studies of amino acids and peptides II. *J. Am. Chem. Soc.* 92: 680~686, 1970